Home Analyzing the capability of PSP, PCT and sCD25 to support the diagnosis of infection in cancer patients with febrile neutropenia
Article
Licensed
Unlicensed Requires Authentication

Analyzing the capability of PSP, PCT and sCD25 to support the diagnosis of infection in cancer patients with febrile neutropenia

  • Luis García de Guadiana-Romualdo EMAIL logo , Enrique Jiménez-Santos , Pablo Cerezuela-Fuentes , Ignacio Español-Morales , Mario Berger , Patricia Esteban-Torrella , Ana Hernando-Holgado and María Dolores Albaladejo-Otón
Published/Copyright: September 21, 2018
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 57 Issue 4

Abstract

Background

Early diagnosis of infection is essential for the initial management of cancer patients with chemotherapy-associated febrile neutropenia (FN). In this study, we have evaluated two emerging infection biomarkers, pancreatic stone protein (PSP) and soluble receptor of interleukin 2, known as soluble cluster of differentiation 25 (sCD25), for the detection of an infectious cause in FN, in comparison with other commonly used infection biomarkers, such as procalcitonin (PCT).

Methods

A total of 105 cancer patients presenting to the emergency department were prospectively enrolled. We observed 114 episodes of chemotherapy-associated FN. At presentation, a blood sample was collected for the measurement of PCT, PSP and sCD25. In order to evaluate the discriminatory ability of these markers for the diagnosis of infection, the area under the curve (AUC) of the receiver operating characteristic curves was calculated.

Results

Infection was documented in 59 FN episodes. PCT, PSP and sCD25 levels were significantly higher in infected patients. PCT was the biomarker with the highest diagnostic accuracy for infection (AUC: 0.901), whereas PSP and sCD25 showed a similar performance, with AUCs of 0.751 and 0.730, respectively. In a multivariable analysis, PCT and sCD25 were shown to be independently associated with infection.

Conclusions

Two novel biomarkers, PSP and sCD25, correlated with infection in cancer patients with chemotherapy-associated FN, but neither PSP nor sCD25 improved the performance of PCT. Based on the results obtained, the introduction of these novel biomarkers as a tool for the diagnosis of infection in this patient group is not recommended.

Keywords: cancer; emergency department; febrile neutropenia; infection; pancreatic stone protein; procalcitonin; soluble cluster of differentiation 25

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: Abbott Laboratories supported the study providing PSP and sCD25 reagents. Abbott GmbH and Co. KG did not participate in the study design or analysis and interpretation of results.

  3. Employment or leadership: MB was employee of Abbott GmbH and Co. KG. Wiesbaden, Germany, when the study was performed. All other authors declare that there is no conflict of interest.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Knight T, Ahn S, Rice TW, Cooksley T. Acute oncology care: a narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors. Eur J Intern Med 2017;45:59–65.10.1016/j.ejim.2017.09.025Search in Google Scholar PubMed

2. Toussaint E, Bahel-Bell E, Vekemans M, Georgala A, Al-Hakak L, Paesmans M, et al. Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer 2006;14:763–9.10.1007/s00520-005-0898-0Search in Google Scholar PubMed

3. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258–66.10.1002/cncr.21847Search in Google Scholar PubMed

4. White L, Ybarra M. Neutropenic fever. Hematol Onc Clin North Am 2017;31:981–93.10.1016/j.hoc.2017.08.004Search in Google Scholar PubMed

5. Fletcher M, Hodgkiss H, Zhang S, Browning R, Hadden C, Hoffman T, et al. Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer. Pediatr Blood Cancer 2013;60:1299–306.10.1002/pbc.24485Search in Google Scholar PubMed

6. Klastersky J, Awada A, Paesmans M, Aoun M. Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 2011;78:185–94.10.1016/j.critrevonc.2010.03.008Search in Google Scholar PubMed

7. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016;27:v111–8.10.1093/annonc/mdw325Search in Google Scholar PubMed

8. Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 2017;96:1775–92.10.1007/s00277-017-3098-3Search in Google Scholar PubMed PubMed Central

9. Wu CW, Wu JY, Chen CK, Huang SL, Hsu SC, Lee MT, et al. Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer 2015;23:2863–72.10.1007/s00520-015-2650-8Search in Google Scholar PubMed

10. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206–17.10.1086/421997Search in Google Scholar PubMed

11. Debiane L, Hachem RY, Al Wohoush I, Shomali W, Bahu R, Jiang Y, et al. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer. Crit Care Med 2014;42:2500–7.10.1097/CCM.0000000000000526Search in Google Scholar

12. Massaro KS, Costa SF, Leone C, Chamone DA. Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 2007;7:137.10.1186/1471-2334-7-137Search in Google Scholar

13. Lin SG, Hou TY, Huang DH, He SY, Lin YD, Zhang LY, et al. Role of procalcitonin in the diagnosis of severe infection in pediatric patients with fever and neutropenia–a systemic review and meta-analysis. Pediatr Infect Dis J 2012;31: e182–8.10.1097/INF.0b013e31825da45dSearch in Google Scholar

14. Lima SS, Nobre V, de Castro Romanelli RM, Clemente WT, da Silva Bittencourt HN, Melo AC, et al. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol 2016;95:1169–76.10.1007/s00277-016-2639-5Search in Google Scholar

15. Watanabe T, Yonekura H, Terazono K, Yamamoto H, Okamoto H. Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene. J Biol Chem 1990;265:7432–9.10.1016/S0021-9258(19)39132-XSearch in Google Scholar

16. Graf R, Schiesser M, Reding T, Appenzeller P, Sun L-K, Fortunato F, et al. Exocrine meets endocrine: pancreatic stone protein and regenerating protein–two sides of the same coin. J Surg Res 2006;133:113–20.10.1016/j.jss.2005.09.030Search in Google Scholar PubMed

17. Keel M, Härter L, Reding T, Sun LK, Hersberger M, Seifert B, et al. Pancreatic stone protein is highly increased during posttraumatic sepsis and activates neutrophil granulocytes. Crit Care Med 2009;37:1642–8.10.1097/CCM.0b013e31819da7d6Search in Google Scholar PubMed

18. Reding T, Palmiere C, Pazhepurackel C, Schiesser M, Bimmler D, Schlegel A, et al. The pancreas responds to remote damage and systemic stress by secretion of the pancreatic secretory proteins PSP/regI and PAP/regIII. Oncotarget 2017;8: 30162–74.10.18632/oncotarget.16282Search in Google Scholar PubMed PubMed Central

19. Venet F, Chung C-S, Monneret G, Huang X, Horner B, Garber M, et al. Regulatory T cell populations in sepsis and trauma. J Leukoc Biol 2007;83:523–35.10.1189/jlb.0607371Search in Google Scholar PubMed

20. Saito K, Wagatsuma T, Toyama H, Ejima Y, Hoshi K, Shibusawa M, et al. Sepsis is characterized by the increases in percentages of circulating CD4+CD25+ regulatory T cells and plasma levels of soluble CD25. Tohoku J Exp Med 2008;216:61–8.10.1620/tjem.216.61Search in Google Scholar PubMed

21. Llewelyn MJ, Berger M, Gregory M, Ramaiah R, Taylor AL, Curdt I, et al. Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care. Crit Care 2013;17:R60.10.1186/cc12588Search in Google Scholar PubMed PubMed Central

22. García de Guadiana-Romualdo L, Berger M, Jiménez-Santos E, Rebollo-Acebes S, Jiménez-Sánchez R, Esteban-Torrella P, et al. Pancreatic stone protein and soluble CD25 for infection and sepsis in an emergency department. Eur J Clin Invest 2017;47:297–304.10.1111/eci.12732Search in Google Scholar PubMed

23. Rass AA, Talat MA, Arafa MA, El-Saadany HF, Amin EK, Abdelsalam MM, et al. The role of pancreatic stone protein in diagnosis of early onset neonatal sepsis. Biomed Res Int 2016;2016:1035856.10.1155/2016/1035856Search in Google Scholar PubMed PubMed Central

24. Que Y-A, Delodder F, Guessous I, Graf R, Bain M, Calandra T, et al. Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management. Crit Care 2012;16:R114.10.1186/cc11406Search in Google Scholar PubMed PubMed Central

25. Que Y-A, Guessous I, Dupuis-Lozeron E, de Oliveira CR, Oliveira CF, Graf R, et al. Prognostication of mortality in critically ill patients with severe infections. Chest 2015;148:674–82.10.1378/chest.15-0123Search in Google Scholar PubMed

26. Wu Q, Nie J, Wu F-X, Zou X-L, Chen F-Y. Prognostic value of high-sensitivity C-reactive protein, procalcitonin and pancreatic stone protein in pediatric sepsis. Med Sci Monit 2017;23: 1533–9.10.12659/MSM.900856Search in Google Scholar PubMed PubMed Central

27. From the International Host Society. The design, analysis and reporting of clinical trial son the empirical antibiotic management of the neutropenic patients. A consensus report. J Infect Dis 1990;161:397–401.10.1093/infdis/161.3.397Search in Google Scholar PubMed

28. Liu X, Feng Wang D, Fang Y, Feng Ye W, Liu S, Lou N. Initial procalcitonin level predicts infection and its outcome in patients with non-Hodgkin lymphoma with febrile neutropenia. Leuk Lymphoma 2015;56:85–91.10.3109/10428194.2014.911864Search in Google Scholar PubMed

29. García de Guadiana-Romualdo L, Español-Morales I, Cerezuela-Fuentes P, Consuegra-Sánchez L, Hernando-Holgado A, Esteban-Torrella P, et al. Value of lypopolysaccharide binding protein as a marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin and interleukin 6. Support Care Cancer 2015;23:2175–82.10.1007/s00520-014-2589-1Search in Google Scholar PubMed

30. Richter ME, Neugebauer S, Engelmann F, Hagel S, Ludewig M, La Rosée P, et al. Biomarker candidates for the detection of an infectious etiology of febrile neutropenia. Infection 2016;44:175–86.10.1007/s15010-015-0830-6Search in Google Scholar PubMed

31. Cisneros-Herreros JM, Cobo-Reinoso J, Pujol-Rojo M, Rodríguez-Baño J, Salavert-Lletí M. Guía para el diagnóstico y tratamiento del paciente con bacteriemia. Guías de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Enferm Infecc Microbiol Clin 2007;25:111–30.10.1016/S0213-005X(07)74242-8Search in Google Scholar

32. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the area under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.10.2307/2531595Search in Google Scholar

33. Yin J, Tian L. Joint confidence region estimation for area under ROC curve and Youden index. Stat Med 2014;33: 985–1000.10.1002/sim.5992Search in Google Scholar PubMed

34. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ 2004;329:168.10.1136/bmj.329.7458.168Search in Google Scholar PubMed PubMed Central

35. Vincent JL. The clinical challenge of sepsis identification and monitoring. PLoS Med 2016;13:e1002022.10.1371/journal.pmed.1002022Search in Google Scholar PubMed PubMed Central

36. Hosmer D, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley-Interscience Publication, 2005.10.1002/0470011815.b2a10029Search in Google Scholar

37. Taplitz RA, Kennedy EB, Bow E, Crews J, Gleason C, Hawley DK, et al. Outpatient of management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of American Clinical Practice Guideline Update. J Clin Oncol 2018;36: 1443–53.10.1200/JCO.2017.77.6211Search in Google Scholar PubMed

38. Martínez-Barroso KA, Burgeño-Lorenzo I, Santos-Rodríguez K, Julián Jiménez A. [The usefulness of infection biomarkers in patients with febrile neutropenia in the Emergency Department]. Enferm Infecc Microbiol Clin 2017;35:395–6.10.1016/j.eimce.2015.09.001Search in Google Scholar

39. Miedema KG, de Bont ES, Elferink RF, van Vliet MJ, Nijhuis CS, Kamps WA, et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer 2011;19:1593–600.10.1007/s00520-010-0987-6Search in Google Scholar PubMed PubMed Central

40. Sbrana A, Torchio M, Comolli G, Antonuzzo A, Danova M; on behalf of the Italian Network for Supportive Care in Oncology (NICSO). Use of procalcitonin in clinical oncology: a literature review. New Microbiol 2016;39:174–80.Search in Google Scholar

41. Bruno B, Busca A, Vallero S, Raviolo S, Mordini N, Nassi L, et al. Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients. Expert Rev Hematol 2017;10:543–50.10.1080/17474086.2017.1326813Search in Google Scholar PubMed

42. Robinson JO, Lamoth F, Bally F, Knaup M, Calandra T, Marchetti O. Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever? PLoS One 2011;6:e18886.10.1371/journal.pone.0018886Search in Google Scholar PubMed PubMed Central

43. Sánchez-Yepes M, Aznar-Oroval E, Lorente-Alegre P, García-Lozano T, Picón-Roig I, Pérez-Ballestero P, et al. [Use of procalcitonin and C-reactive protein as infection markers in febrile neutropenic patients undergoing haematopoietic stem cell transplant]. Enferm Infecc Microbiol Clin 2014;32: 418–23.10.1016/j.eimc.2013.09.003Search in Google Scholar PubMed

44. Bartoletti M, Antonelli M, Bruno Blasi FA, Casagranda I, Chieregato A, Fumagalli R, et al. Procalcitonin-guided antibiotic therapy: an expert consensus. Clin Chem Lab Med 2018;26:1223–9.10.1515/cclm-2018-0259Search in Google Scholar PubMed

45. Diness LV, Maraldo MV, Mortesen CE, Mellemgaard A, Larsen FO. Procalcitonin and C-reactive protein as markers of bacterial infection in patients with solid tumours. Dan Med J 2014;61:A4984.Search in Google Scholar

46. García de Guadiana Romualdo L, Esteban Torrella P, Rebollo Acebes S, Albaladejo Otón MD, Jiménez Sánchez R, Hernando Holgado A, et al. Diagnostic accuracy of presepsin (sCD14-ST) as a biomarker of infection and sepsis in the emergency department. Clin Chim Acta 2017;464:6–11.10.1016/j.cca.2016.11.003Search in Google Scholar PubMed

47. Engel A, Steinbach G, Kern P, Kern WW. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 1999;31:185–9.10.1080/003655499750006254Search in Google Scholar PubMed

48. Carnino L, Betteto S, Loiacono M, Chiapella A, Giacobino A, Ciuffreda L, et al. Procalcitonin as a predictive marker of infections in chemo-induced neutropenia. J Cancer Res Clin Oncol 2010;136:611–6.10.1007/s00432-009-0699-9Search in Google Scholar PubMed

49. Chaftari AM, Hachem R, Reitzel R, Jordan M, Jiang Y, Yousif A, et al. Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. PLos One 2015;10:e0130999.10.1371/journal.pone.0130999Search in Google Scholar PubMed PubMed Central

50. Tan BH, Png ME, Yeo CP, Wong GC. Procalcitonin in febrile neutropenia-timing is important. Support Care Cancer 2014;22:583–4.10.1007/s00520-013-2078-ySearch in Google Scholar PubMed

Received: 2018-02-10
Accepted: 2018-08-16
Published Online: 2018-09-21
Published in Print: 2019-03-26

©2019 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Can Grail find the trail to early cancer detection?
  4. Reviews
  5. Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey
  6. Application of NMR metabolomics to search for human disease biomarkers in blood
  7. Mini Review
  8. Host-response biomarkers for the diagnosis of bacterial respiratory tract infections
  9. Opinion Paper
  10. Diabetes alert dogs: a narrative critical overview
  11. EFLM Paper
  12. Documenting metrological traceability as intended by ISO 15189:2012: A consensus statement about the practice of the implementation and auditing of this norm element
  13. General Clinical Chemistry and Laboratory Medicine
  14. Commutability of external quality assessment materials for serum sodium and potassium measurements
  15. Standardization of measurement procedures for serum uric acid: 8-year experience from Category 1 EQA program results in China
  16. Next-generation rapid serum tube technology using prothrombin activator coagulant: fast, high-quality serum from normal samples
  17. Cannabinoids determination in bronchoalveolar lavages of cannabis smokers with lung disease
  18. A new method for the determination of ammonium in the vitreous humour based on capillary electrophoresis and its preliminary application in thanatochemistry
  19. Reference Values and Biological Variations
  20. Defining reference intervals for a serum growth differentiation factor-15 (GDF-15) assay in a Caucasian population and its potential utility in diabetic kidney disease (DKD)
  21. Cancer Diagnostics
  22. Preanalytical stability of [-2]proPSA in whole blood stored at room temperature before separation of serum and plasma: implications to Phi determination
  23. Cardiovascular Diseases
  24. A de novo mutation of SMYD1 (p.F272L) is responsible for hypertrophic cardiomyopathy in a Chinese patient
  25. Infectious Diseases
  26. Analyzing the capability of PSP, PCT and sCD25 to support the diagnosis of infection in cancer patients with febrile neutropenia
  27. Mid-regional pro-adrenomedullin predicts poor outcome in non-selected patients admitted to an intensive care unit
  28. Validation of Mycobacterium tuberculosis real-time polymerase chain reaction for diagnosis of tuberculous meningitis using cerebrospinal fluid samples: a pilot study
  29. Letters to the Editor
  30. Methodological issues are important in cannabinoids determination in bronchoalveolar lavage
  31. Clarifying methodological issues in cannabinoids determination in bronchoalveolar lavages
  32. Letter to the Editor relating to Clin Chem Lab Med 2018;56(7):1090–1099
  33. Authors’ reply to the Letter by Infantino et al. commenting on Bonroy et al.: Anti-DFS70 in different settings, CCLM 2018;56:1090–9
  34. High-sensitivity cardiac troponin-I analytical imprecisions evaluated by internal quality control or imprecision profile
  35. Procalcitonin as guide to therapy in endovascular infections: caveat emptor!
  36. A new suggested approach in screening for Bence Jones protein and potential kidney damage
  37. Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia
  38. Parallel algorithm for myeloproliferative neoplasms testing: the frequency of double mutations is found in the JAK2/MPL genes more often than the JAK2/CALR genes, but is there a clinical benefit?
  39. CGH array for the identification of a compound heterozygous mutation in the CYP1B1 gene in a patient with bilateral anterior segment dysgenesis
  40. A very rare interference with the valproate method on the Beckman DxC 800 general chemistry analyser
  41. Congress Abstracts
  42. 5th EFLM Conference on Preanalytical Phase Zagreb (HR), 22-23 March 2019
https://doi.org/10.1515/cclm-2018-0154
Keywords for this article
cancer; emergency department; febrile neutropenia; infection; pancreatic stone protein; procalcitonin; soluble cluster of differentiation 25

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Can Grail find the trail to early cancer detection?
  4. Reviews
  5. Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey
  6. Application of NMR metabolomics to search for human disease biomarkers in blood
  7. Mini Review
  8. Host-response biomarkers for the diagnosis of bacterial respiratory tract infections
  9. Opinion Paper
  10. Diabetes alert dogs: a narrative critical overview
  11. EFLM Paper
  12. Documenting metrological traceability as intended by ISO 15189:2012: A consensus statement about the practice of the implementation and auditing of this norm element
  13. General Clinical Chemistry and Laboratory Medicine
  14. Commutability of external quality assessment materials for serum sodium and potassium measurements
  15. Standardization of measurement procedures for serum uric acid: 8-year experience from Category 1 EQA program results in China
  16. Next-generation rapid serum tube technology using prothrombin activator coagulant: fast, high-quality serum from normal samples
  17. Cannabinoids determination in bronchoalveolar lavages of cannabis smokers with lung disease
  18. A new method for the determination of ammonium in the vitreous humour based on capillary electrophoresis and its preliminary application in thanatochemistry
  19. Reference Values and Biological Variations
  20. Defining reference intervals for a serum growth differentiation factor-15 (GDF-15) assay in a Caucasian population and its potential utility in diabetic kidney disease (DKD)
  21. Cancer Diagnostics
  22. Preanalytical stability of [-2]proPSA in whole blood stored at room temperature before separation of serum and plasma: implications to Phi determination
  23. Cardiovascular Diseases
  24. A de novo mutation of SMYD1 (p.F272L) is responsible for hypertrophic cardiomyopathy in a Chinese patient
  25. Infectious Diseases
  26. Analyzing the capability of PSP, PCT and sCD25 to support the diagnosis of infection in cancer patients with febrile neutropenia
  27. Mid-regional pro-adrenomedullin predicts poor outcome in non-selected patients admitted to an intensive care unit
  28. Validation of Mycobacterium tuberculosis real-time polymerase chain reaction for diagnosis of tuberculous meningitis using cerebrospinal fluid samples: a pilot study
  29. Letters to the Editor
  30. Methodological issues are important in cannabinoids determination in bronchoalveolar lavage
  31. Clarifying methodological issues in cannabinoids determination in bronchoalveolar lavages
  32. Letter to the Editor relating to Clin Chem Lab Med 2018;56(7):1090–1099
  33. Authors’ reply to the Letter by Infantino et al. commenting on Bonroy et al.: Anti-DFS70 in different settings, CCLM 2018;56:1090–9
  34. High-sensitivity cardiac troponin-I analytical imprecisions evaluated by internal quality control or imprecision profile
  35. Procalcitonin as guide to therapy in endovascular infections: caveat emptor!
  36. A new suggested approach in screening for Bence Jones protein and potential kidney damage
  37. Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia
  38. Parallel algorithm for myeloproliferative neoplasms testing: the frequency of double mutations is found in the JAK2/MPL genes more often than the JAK2/CALR genes, but is there a clinical benefit?
  39. CGH array for the identification of a compound heterozygous mutation in the CYP1B1 gene in a patient with bilateral anterior segment dysgenesis
  40. A very rare interference with the valproate method on the Beckman DxC 800 general chemistry analyser
  41. Congress Abstracts
  42. 5th EFLM Conference on Preanalytical Phase Zagreb (HR), 22-23 March 2019
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2018-0154/html
Scroll to top button